Medtronic is looking make its device the first to be FDA-approved for long-running atrial fibrillation, shaking off a 2011 setback and kicking-starting enrollment in a new pivotal trial.
Topera Medical picked up FDA clearance for the latest generation of its 3-D Mapping System, a device designed to help diagnose cardiac arrhythmias without invasive surgery.
AtriCure is set to acquire California-based surgical ablation device maker Estech in a deal worth at least $34 million and almost double that amount down the line.
Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety profile, but the drug may struggle to carve out market share in a cluttered space.
Boston Scientific is ticking closer to judgment day for its much-scrutinized Watchman device, securing an FDA advisory hearing for a stroke-fighting implant that has faced doubts throughout its development.
Patients with atrial fibrillation, a common cardiac arrhythmia, are often at a heightened risk for stroke and other health problems. But researchers in the U.K. and elsewhere believe they have identified a biomarker that can help screen for folks who face a greater likelihood of complications.
Heart failure patients treated with a Medtronic defibrillator were roughly half as likely to endure atrial fibrillation than were those using other devices, according to a study.
After a three-year legal spat, Gore has prevailed over St. Jude Medical and can keep its heart plug on the market, the company said.
Isis Pharmaceuticals has opted to throw in the towel on its rheumatoid arthritis program for ISIS-CRP Rx, but the biotech says it will continue to plug away at studies of the antisense treatment for other diseases, including a mid-stage trial for atrial fibrillation due to read out next year.
AtriCure produced double-digit revenue increases in its 2013 second quarter on the strength of expanded sales for its ablation devices to treat atrial fibrillation. But losses remained, as the company ramped up spending to promote and sell its offerings in the U.S. and internationally.